Gilead Sciences (FRA:GIS) Total Receivables: €4,101 Mil (As of Mar. 2026)


FRA:GIS Gilead Sciences Inc FRA:GIS
69 GF Score
Price €117.50
GF Value €82.35
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Gilead Sciences Total Receivables?

Gilead Sciences FRA:GIS +4.15% 69 Total Receivables is €4,101 Mil as of Mar. 2026. GuruFocus rates FRA:GIS with a GF Score™ of 69/100 and a GF Value™ of €82.35 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Gilead Sciences's Total Receivables for the quarter that ended in Mar. 2026 was €4,101 Mil.

Gilead Sciences Total Receivables Related Terms

Gilead Sciences Total Receivables Historical Data

* Premium members only.

The historical data trend for Gilead Sciences's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences Total Receivables Chart

Gilead Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,976.31 4,509.49 4,273.22 4,221.10 4,195.70

Gilead Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,058.90 4,145.13 4,340.94 4,195.70 4,100.97
FRA:GIS
69GF Score
Gilead Sciences Inc FRA:GIS
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gilead Sciences Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €4,101 Mil mean?
Gilead Sciences (FRA:GIS) has a Total Receivables of €4,101 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Gilead Sciences and its competitors.
Is Gilead Sciences' Total Receivables too high?
Gilead Sciences' current Total Receivables is €4,101 Mil. Overall, Gilead Sciences has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Total Receivables compare to PFE and AMGN?
Gilead Sciences' Total Receivables of €4,101 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Gilead Sciences and its competitors. Gilead Sciences's current Total Receivables is €4,101 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €82.35, compared to a current price of €117.50 — trading 42.7% above its estimated fair value. The current Total Receivables is €4,101 Mil. Gilead Sciences' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current Total Receivables is €4,101 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gilead Sciences (FRA:GIS) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of €117.50 is trading 42.7% above its estimated GF Value™ of €82.35. GuruFocus considers Gilead Sciences to be Significantly Overvalued.

Key valuation signals for FRA:GIS:

  • Total Receivables: €4,101 Mil
  • GF Value™: €82.35 vs. price of €117.50 (42.7% above fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
69GF Score

Get the complete analysis for FRA:GIS

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€117.50
Price
€82.35
GF Value